ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.520
+0.090 (2.62%)
Jul 10, 2026, 10:53 AM HKT
Market Cap1.48B -73.1%
Revenue (ttm)171.70M +108.1%
Net Income-243.24M
EPS-0.59
Shares Out 431.51M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,600
Open3.450
Previous Close3.430
Day's Range3.410 - 3.520
52-Week Range2.800 - 16.800
Beta0.22
Analystsn/a
Price Targetn/a
Earnings DateAug 21, 2026

About HKG:1541

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical tria... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 202
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1541
Full Company Profile

Financial Performance

In 2025, HKG:1541's revenue was 154.29 million, an increase of 108.09% compared to the previous year's 74.15 million. Losses were -218.58 million, -30.80% less than in 2024.

Financial numbers in CNY Financial Statements